±¹¼Ò ÁøÇàµÈ ºñ¼Ò¼¼Æ÷¼º Æó¾Ï¿¡¼ À¯µµ ÈÇпä¹ý ¹× ¹æ»ç¼±Ä¡·á
Induction Chemotherapy and Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
¼Ò¼Ó »ó¼¼Á¤º¸
À±»ó¸ð/Sang Mo Yun
±èÀçö/¹ÚÀαÔ/À±»ó¸ð/±èÀçö/¹ÚÀαÔ/Jae Cheol Kim/In Kyu Park/Sang Mo Yun/Jae Cheol Kim/In Kyu Park
KMID : 0859319990170030195
Abstract
¸ñ Àû : ±¹¼Ò ÁøÇàµÈ ºñ¼Ò¼¼Æ÷¼º Æó¾ÏÀÇ Ä¡·á¿¡ ÀÖ¾î¼ ¿¹ÈÄ ÀÎÀÚ¸¦ ºÐ¼®ÇÏ°í, À¯µµ ÈÇÐ
¿ä¹ýÀÌ »ýÁ¸À² ¹× Ä¡·á½ÇÆÐ ¾ç»ó¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ¾Ë¾Æº¸°íÀÚ º» ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : 1986³â 1¿ùºÎÅÍ 1996³â 10¿ù±îÁö ±¹¼Ò ÁøÇàµÈ ºñ¼Ò¼¼Æ÷¼º Æó¾ÏÀ¸·Î Áø´Ü
¹Þ°í ±ÙÄ¡Àû ¸ñÀûÀ¸·Î ¹æ»ç¼±Ä¡·á ȤÀº º´ÇÕ¿ä¹ý(À¯µµ ÈÇпä¹ý ¹× ¹æ»ç¼±Ä¡·á)À» ¹ÞÀº 130
¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÈÄÇâÀû ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù. ¹æ»ç¼±Ä¡·á ´Üµ¶±ºÀÌ 85¸í, º´ÇÕ¿ä¹ý ±ºÀÌ
45¸íÀ̾ú´Ù. ¿¬·É, ¼ºº°, Àü½Å ¼öÇà´É·Â, º´¸®Á¶Á÷ÇÐÀû À¯Çü, ±×¸®°í º´±â µîÀº ¾ç±º¿¡¼ °í
¸£°Ô ºÐÆ÷ÇÏ¿´´Ù. ¹æ»ç¼±Ä¡·á´Â 6 MV ȤÀº 10 MV ¼±Çü°¡¼Ó±â¸¦ »ç¿ëÇÏ¿´°í, ÀÏÀÏ ¼±·®
1.8¡2.0 §í¸¦ ÁÖ 5ȸ Á¶»çÇÏ¿´´Ù. ÃÑ ¹æ»ç¼±·®Àº 129¸í¿¡¼ 59.6 §í ÀÌ»ó(56¡66 §í, Áß¾Ó°ª
60 §í) Á¶»çµÇ¾ú´Ù. À¯µµ ÈÇпä¹ýÀº 2¡5ȸ(Áß¾Ó°ª 2ȸ) ½ÃÇàÇÏ¿´´Ù. »ç¿ëµÈ ¾àÁ¦´Â CAP
(Cyclophosphamide, Adriamycin, Cisplatin)°¡ 6¸í, MVP (Mitomycin, Vinblastine,
Cisplatin)°¡ 9¸í, MIC (Mitomycin, Ifosfamide Cisplatin)ÀÌ 13·Ê, ±×¸®°í EP(Etoposide,
Clsplatin)°¡ 17¸í¿¡¼ ½ÃÇàµÇ¾úÀ¸¸ç, ¸ðµç ¿ä¹ýÀÌ Cis-platinumÀ» Æ÷ÇÔÇÏ¿´´Ù.
°á °ú : Àüü ȯÀÚÀÇ »ýÁ¸À²Àº 1, 2, 3 ³â Àüü »ýÁ¸À²ÀÌ °¢°¢ 41.5, 13.7, 7% ¿´°í, Áß¾Ó
»ýÁ¸±â°£Àº 11°³¿ùÀ̾ú´Ù. Ä¡·á ¹æ¹ýº° 1, 2, 3 ³â Àüü »ýÁ¸À², ±×¸®°í Áß¾Ó »ýÁ¸±â°£Àº, ¹æ
»ç¼±Ä¡·á ´Üµ¶±ºÀÇ °æ¿ì °¢°¢ 32.9, 10.5, 6%, 9°³¿ùÀ̾úÀ¸¸ç, º´ÇÕ¿ä¹ý ±ºÀÇ °æ¿ì´Â °¢°¢
57.8, 20, 7.6%, 14 °³¿ùÀ̾ú´Ù(p=0.0005). ÃÖÁ¾ Ä¡·á ¹ÝÀÀÀ» °üÂûÇÒ ¼ö ÀÖ¾ú´ø 126¸í Áß 38¸í
(30.2%)¿¡¼ ¿ÏÀü°üÇظ¦ º¸¿´°í, Ä¡·á ¹æ¹ýº°·Î ³ª´©¾î ºÐ¼®ÇÏ¿´À» °æ¿ì, ¹æ»ç¼±Ä¡·á ´Üµ¶±º
¿¡¼ ¿ÏÀü°üÇØ°¡ 25% (21/84), º´ÇÕ¿ä¹ý ±ºÀÇ °æ¿ì´Â 40.5% (17/42)¿¡¼ ¿ÏÀü°üÇظ¦ º¸¿´´Ù
(p=0.09). »ýÁ¸À²¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿¹ÈÄ ÀÎÀÚ´Â Ç÷»ö¼ÒÄ¡(p=0.04), NSE (neuron-specific
enolase)Ä¡(p=0.004), ±×¸®°í ÃÖÁ¾ Ä¡·á ¹ÝÀÀ(p=0.004) µîÀ̾ú´Ù. Ä¡·á ¹æ¹ýº°·Î ³ª´©¾î¼ ºÐ
¼®ÇÑ °á°ú, ¹æ»ç¼±Ä¡·á ´Üµ¶±ºÀÇ °æ¿ì´Â NSEÄ¡(p=0.006)¿Í ÃÖÁ¾ Ä¡·á ¹ÝÀÀ(p=0.003), º´ÇÕ¿ä
¹ý±ºÀÇ °æ¿ì´Â ÃÖÁ¾ Ä¡·á¹ÝÀÀ(p=0.007)ÀÌ ¿¹ÈÄ ÀÎÀÚ¿´´Ù. Ä¡·á ½ÇÆоç»óÀº ÃßÀû °üÂûÀÌ °¡´É
Çß°í Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀÀ» ¾Ë ¼ö ÀÖ¾ú´ø 120¸íÀ» ´ë»óÀ¸·Î ºÐ¼®ÇÑ °á°ú, ¾ç±º°£¿¡ ƯÀÌÇÑ Â÷
À̸¦ º¸ÀÌÁö ¾Ê¾Ò´Ù. ±×·¯³ª, Ä¡·á¿¡ ¿ÏÀü°üÇظ¦ º¸ÀΠȯÀÚµéÀ» ´ë»óÀ¸·Î »ìÆ캸¸é º´ÇÕ¿ä¹ý
±º¿¡¼ ¿ø°ÝÀüÀÌ°¡ °¨¼ÒÇÏ´Â °æÇâÀ» º¸¿´´Âµ¥, ¹æ»ç¼±Ä¡·á ´Üµ¶±ºÀº 19¸íÁß 11¸í¿¡¼, º´ÇÕ
¿ä¹ý ±ºÀº 13¸íÁß 3¸í¿¡¼ ¿ø°ÝÀüÀÌ°¡ ¹ß°ßµÇ¾ú´Ù(p=0.07). ±¹¼Ò ½ÇÆд ¿ÏÀü°üÇظ¦ º¸ÀΠȯ
ÀÚ¿¡¼µµ ¾ç±º¿¡¼ Â÷ÀÌ°¡ ¾ø¾ú´Ù(10/19 vs 6/13).
°á ·Ð : ±¹¼Ò ÁøÇàµÈ ºñ¼Ò¼¼Æ÷¼º Æó¾ÏÀÇ °æ¿ì À¯µµ ÈÇпä¹ýÀ» ½ÃÇàÇÔÀ¸·Î½á, ¹æ»ç¼±Ä¡·á
´Üµ¶º¸´Ù 2³â »ýÁ¸À²ÀÌ Çâ»óµÇ¾ú°í, Àû¾îµµ ¿ÏÀü°üÇظ¦ º¸ÀÎ °æ¿ì´Â ¿ø°ÝÀüÀÌ°¡ °¨¼ÒÇÏ´Â
°æÇâÀ» º¸¿´´Ù. ±×·¯³ª, ±¹¼Ò ½ÇÆÐ ¾ç»ó ¹× Àå±â »ýÁ¸À²¿¡´Â À¯µµ ÈÇпä¹ýÀÌ µµ¿òÀÌ µÇÁö
¾Ê¾Ò´Ù. µû¶ó¼, ±¹¼ÒÁ¦¾îÀ²À» ³ôÀ̱â À§ÇÑ ´Ù°¢ÀûÀÎ ³ë·ÂÀÌ ¿ä±¸µÈ´Ù.
Purpose : We performed this study to evaluate the prognostic factors and the effect of
induction chemotherapy in locally advanced non-small cell lung cancel (NSCLC).
Materials and Methods : A retrospective analysis was done for 130 patients with
locally advanced NSCLC treated with curative radiotherapy alone or induction
chemo-radiotherapy from January 1986 to October 1996. Eighty-five patients were
treated with radiotherapy alone, forty-five with induction chemotherapy and radiotherapy.
Age, sex, performance status, histopathologic type, and stage were evenly distributed in
both groups. The patients were treated with 6 MV or 10 MV X-ray. Conventional
fractionation with daily fraction size 1.8¡2.0 §í was done. Of the patients, 129 patients
received total dose above 59.6 §í (56¡66 §í, median 60 §í). Induction chemotherapy
regimen were CAP (Cyclophosphamide, Adriamycin, Cisplatin) in 6 patients, MVP
(Mitomycin, Vinblastine, Cisplatin) in 9 patients, MIC (Mitomycin, Ifosfamide Cisplatin)
in 13 patients, and EP (Etoposide, Cisplatin) in 17 patients. Chemotherapy was done in
2¡5 cycles (median 2).
Results : Overall 1-, 2-, and 3-year survival rate (YSR) for all patients were 41.5%,
13.7%, and 7%, respectively (median survival time 11 months). According to treatment
modality, median survival time, overall 1-, 2-, and 3-YSR were 9 months, 32.9%, 10.5%,
6% for radiotherapy alone group, and 14 months, 57.8%, 20%, 7.6% for induction
chemotherapy group, respectively (p=0.0005). Complete response (CR) to overall
treatments was 25% (21/84) in radiotherapy alone and 40.5% (17/42) in induction
chemotherapy group (P=0.09). The Prognostic factors affecting overall survival were
hemoglobin level (p=0.04), NSE (neuron-specific enolase) level (p=0.004), and response to
overall treatment(p=0.004). According to treatment modalities, NSE (neuron-specific
enolase) (p=0.006) and response to overall treatment (p=0.003) were associated with
overall survival in radiotherapy alone group, and response to overall treatment (p=0.007)
in induction chemotherapy group. The failure pattern analysis revealed no significant
difference between treatment modalities. But, in patients with CR to overall treatment,
distant metastasis were found in 11/19 patients with radiotherapy alone, arid 3/13
patients with induction chemotherapy and radiotherapy (p=0.07). Locoregional failure
patterns were not different between two groups (10/19 vs 6/13).
Conclusion : Induction chemotherapy and radiotherapy achieved increased 2YSR
compared to radio-therapy alone. At least in CR patients, there was decreased tendency
in distant metastasis with induction chemotherapy But, locoregional failures and
long-term survival were not improved. Thus, there is need of more effort to increasing
local control and further decreasing distant metastasis.
Å°¿öµå
ºñ¼Ò¼¼Æ÷¼º Æó¾Ï; À¯µµ ÈÇпä¹ý; ¹æ»ç¼±Ä¡·á; Non-Small cell lung cancer; Induction chemotherapy; Radiotherapy;
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸